Cytokine genetic polymorphisms and prostate cancer aggressiveness

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1358-1362

  Zabaleta, Jovanny ^a   Su, L Joseph ^b   Lin, Hui Yi ^c   Sierra, Rosa A ^a   Hall, M Craig ^d   Sartor, A Oliver ^e   Clark, Peter E ^f   Hu, Jennifer J ^g   Ochoa, Augusto C ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Piedmont Urological Associates   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DNA;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; CYTOKINE PRODUCTION; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; CYTOKINES; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 69449087380     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp124     Document Type: Article

References (44)

1. Parkin, D. M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. American Cancer Society. (2007) Cancer Facts and Figures. www.cancer.org. (Nov 2008, date last accessed).
3. Schaid, D. J. (2004) The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet., 13 Spec No. 1, R103-R121.
4. Jemal, A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
5. National Cancer Institute. (2007) Surveillance, Epidemiology and End Results. http://seer.cancer.gov/. (Nov 2008, date last accessed).
6. Carter, B. S. et al. (1993) Hereditary prostate cancer: epidemiologic and clinical features. J. Urol., 150, 797-802.
7. Lesko, S. M. et al. (1996) Family history and prostate cancer risk. Am. J. Epidemiol., 144, 1041-1047.
8. Johns, L. E. et al. (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int., 91, 789-794.
9. Lichtenstein, P. et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
10. Ahlbom, A. et al. (1997) Cancer in twins: Genetic and nongenetic familial risk factors. J. Natl. Cancer Inst., 89, 287-293.
11. Aprikian, A. G. et al. (1994) Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151, 126-1280.
12. Bookstein, R. et al. (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl Acad. Sci. USA, 87, 7762-7766.
13. Bookstein, R. et al. (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53, 3369-3373.
14. Carter, B. S. et al. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl Acad. Sci. USA, 87, 8751-8755.
15. Latil, A. et al. (1994) Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer, 11, 119-125.
16. Richmond, P. J. et al. (1997) Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival. Cancer Res., 57, 3189-3193.
17. Coussens, L. M. et al. (2001) Inflammatory cells and cancer: Think different!. J. Exp. Med., 193, F23-F26.
18. Coussens, L. M. et al. (2002) Inflammation and cancer. Nature 420, 860-867.
19. MacLennan, G. T. et al. (2006) The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J. Urol., 176, 1012-1016.
20. Allavena, P. et al. (2000) The chemokine receptor switch paradigm and dendritic cell migration: Its significance in tumor tissues. Immunol. Rev., 177, 141-149.
21. Jonjic, N. et al. (1992) Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J. Exp. Med., 176, 1165-1174.
22. Schoppmann, S. F. et al. (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol., 161, 947-956.
23. Torisu, H. et al. (2000) Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int. J. Cancer, 85, 182-188.
24. Alpizar-Alpizar, W. et al. (2005) Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. Clin. Exp. Med., 5, 169-176.
25. El-Omar, E. M. et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404 398-402.
26. Machado, J. C. et al. (2001) Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology, 121, 823-829.
27. Machado, J. C. et al. (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 125, 364-371.
28. Rad, R. et al. (2004) Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut, 53, 1082-1089.
29. Turner, D. M. et al. (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet., 24, 1-8.
30. Zabaleta, J. et al. (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29, 573-578.
31. Hu, J. J. et al. (2004) Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res., 64 1197-1201.
32. Lockett, K. L. et al. (2006) DNA damage levels in prostate cancer cases and controls. Carcinogenesis, 27, 1187-1193.
33. Schroeder, J. C. et al. (2006) The North Carolina-Louisiana Prostate Cancer Project (PCaP): Methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate, 66, 1162-1176.
34. Plaskon, L. A. et al. (2003) Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol. Biomarkers Prev., 12, 604-609.
35. Lin, D. Y. et al. (2008) Simple and efficient analysis of disease association with missing genotype data. Am. J. Hum. Genet., 82 444-452.
36. Lin, H. Y. et al. (2008) Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP-SNP interactions and their application in prostate cancer. J. Hum. Genet. 53, 802-811.
37. Zabaleta, J. et al. (2006) Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am. J. Gastroenterol., 101, 163-171.
38. Correa, P. et al. (1990) Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res., 50, 4737-4740.
39. Michaud, D. S. et al. (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res., 66, 4525-4530.
40. Xu, J. et al. (2005) The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., 14, 2563-2568.
41. Pociot, F. et al. (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest., 22, 396-402.
42. Canedo, P. et al. (2008) The interleukin-8-251* T/* A polymorphism is not associated with risk for gastric carcinoma development in a Portuguese population. Eur. J. Cancer Prev., 17, 28-32.
43. Eschrich, S. et al. (2005) Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol., 23 3526-3535.
44. Shedden, K. et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat. Med., 14, 822-827.